Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Fitzal, F; Filipits, M; Rudas, M; Greil, R; Dietze, O; Samonigg, H; Lax, S; Herz, W; Dubsky, P; Bartsch, R; Kronenwett, R; Gnant, M.
The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial.
Br J Cancer. 2015; 112(8):1405-1410 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Samonigg Hellmut
Altmetrics:

Dimensions Citations:

Plum Analytics:
Number of Figures: 3
| | |
Abstract:
The aim of this study was to examine whether EndoPredict (EP), a novel genomic expression test, is effective in predicting local recurrence (LR)-free survival (LRFS) following surgery for breast cancer in postmenopausal women. In addition, we examined whether EP may help tailor local therapy in these patients. From January 1996 to June 2004, 3714 postmenopausal patients were randomly assigned to either tamoxifen or tamoxifen followed by anastrozole within the prospective ABCSG 8 trial. Using assay scores from EP, we classified breast tumour blocks as either low or high risk for recurrence. Data were gathered from 1324 patients. The median follow-up was 72.3 months and the cumulative incidence of LR was 2.6% (0.4% per year). The risk of LR over a 10-year period among patients with high-risk lesions (n=683) was significantly higher (LRFS=91%) when compared with patients with low-risk lesions (n=641) (10-year LRFS=97.5%) (HR: 1.31 (1.16-1.48) P<0.005). The groups that received breast conservation surgery (BCT) and mastectomy (MX) had similar LR rates (P=0.879). Radiotherapy (RT) after BCT significantly improved LRFS in the cohorts predicted by EP to be low-risk for LR (received RT: n=436, 10-year LRFS 99.8%; did not receive RT: n=63, 10-year LRFS 83.6%, P<0.005). EndoPredict is an effective prognostic tool for predicting LRFS. Among postmenopausal, low-risk patients, EP does not appear to be useful for tailoring local therapy.
Find related publications in this database (using NLM MeSH Indexing)
Adult -
Aged -
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Breast Neoplasms - genetics
Breast Neoplasms - pathology
Breast Neoplasms - therapy
Female -
Humans -
Middle Aged -
Neoplasm Recurrence, Local - genetics
Neoplasm Recurrence, Local - pathology
Postmenopause -
Prospective Studies -
RNA, Neoplasm - analysis
Reagent Kits, Diagnostic -
Receptor, ErbB-2 - genetics
Receptors, Estrogen - genetics
Risk Factors -

Find related publications in this database (Keywords)
breast-conservation
radiotherapy
breast surgery
genomic risk
ABCSG 8
© Meduni Graz Impressum